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Ethanol extract of Swertia chirata was assessed for its thrombolytic, anti-inflammatory activity and phytochemical 
screening. In vitro anti-inflammatory activity was evaluated using albumin denaturation. Aspirin was used as a 
standard drug for the study of anti-inflammatory activity. The ethanol extract of Swertia chirata showed mean 
inhibition of protein denaturation 45.31±0.000576 whereas, for control group it was found to be 50.00±0.00177. In 
thrombolytic activity using in vitro clot lysis assay method, the crude ethanol extract was found to have significant, 
thrombolytic test showed a maximum effect of 40.38% while the standard streptokinase showed 69.35.  
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1. Introduction 
Medicinal plants have always been considered a 
healthy source of life for all people. 
Therapeutically properties of medical plants are 
very useful in healing various diseases and the 
advantage of these medicinal plants is being 
100% natural. 
Nowadays people are being bombarded with 
thousands of unhealthy products, the level of 
sensibility in front of diseases is very high and 
that's why the use of medicinal plants can 
represent the best solution.  Since antiquity, man 
has used plants to treat common infectious 
diseases and even long before mankind 
discovered the existence of microbes; the idea 
that certain plants had healing potential was well 
accepted[1]. A medicinal plant is any plant which, 
in one or more of its organs, contains substances 
that can be used for therapeutic purpose or which 
are precursors for the synthesis of useful drugs. A 
number of plants have been used in traditional 
medicine for many years due to their 
antimicrobial properties[2]. Specifically, the 
medicinal value of these plants lies in some 
chemical substances that produce a definite 
physiological action on the human or animal 
body[3]. The most important of these bioactive 
constituents which are mainly secondary 
metabolites are alkaloids, flavonoids, tannins and 
phenolic compounds. These phytochemicals are 
toxic to microbial cells. 
Inflammation is considered as a primary 
physiologic defense mechanism that helps body 
to protect itself against infection, burn, toxic 
chemicals, allergens or other noxious stimuli. An 
uncontrolled and persistent inflammation may act Journal of Pharmacognosy and Phytochemistry 
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as an etiologic factor for many of these chronic 
illnesses. Although it is a defense mechanism, the 
complex events and mediators involved the 
inflammatory reaction can induce, maintain or 
aggravate many diseases. Currently used 
synthetic anti-inflammatory drugs are associated 
with some severe side effects. Therefore, the 
development of potent anti-inflammatory drugs 
with fewer side effects is necessary from 
medicinal plants origin. 
 
  A blood clot (thrombus) developed in the 
circulatory system due to failure of hemostasis 
causes vascular blockage and while recovering 
leads to serious consequences in 
atherothrombotic diseases such as myocardial or 
cerebral infarction, at times leading to death.[5] 
Thrombolytic agents that include tissue 
plasminogen activator (t-PA), Urokinase (UK), 
streptokinase (SK) etc. are used all over the world 
for the treatment of these diseases. In India, 
though SK and UK are widely used due to lower 
cost,[6,7] as compared to other thrombolytic drugs, 
their use is associated with hyper risk of 
hemorrhage[8]  severe anaphylactic reaction and 
lacks specificity. Moreover, as a result of 
immunogenicity multiple treatments with SK in a 
given patient are restricted[9]. Because of the 
shortcomings of the available thrombolytic drugs, 
attempts are underway to develop improved 
recombinant variants of these drugs[10 – 14]. 
 
Herbal products are often perceived as safe 
because they are "natural".15 In India, in recent 
years, there is increased research on traditional 
ayurvedic herbal medicines on the basis of their 
known effectiveness in the treatment of ailments 
for which they have been traditionally applied. 
Considerable efforts have been directed towards 
the discovery and development of natural 
products from various plant and animal sources 
which have antiplatelet[16, 17], anticoagulant,[18, 19] 
antithrombotic  [20], and thrombolytic activity. 
Epidemiologic studies have provided evidence 
that foods with experimentally proved 
antithrombotic effect could reduce risk of 
thrombosis. Herbs showing thrombolytic activity 
have been studied and some significant 
observations have been reported[21]. 
 
The aim of present study was to screen extracts of 
Swertia chirata for its clot lysis property 
(thrombolytic activity) and anti-inflammatory 
activity by using an in-vitro procedure. Plant-
derived drugs remain an important resource, 
especially  in developing countries, to combat 
serious diseases. Approximately  60–80% of  the 
world's population still relies on traditional 
medicines for the treatment of common illnesses. 
Medicinal plants have a long-standing history in 
many locations in Bangladesh  and continue to 
provide useful and  applicable tools for treating 
ailments. Nevertheless, little scientific research 
was done to investigate the plants Swertia 
chirata.   
 
The activities have been selected because of their 
great medicinal  relevance. Within the recent 
years, Heart diseases have increased  to a great 
extent and side effects of synthetic drug becomes 
an ever-increasing therapeutic problem .4 Because 
natural products of higher plants may give a new 
source of  thrombolytic  agents, as well as anti-
inflammatory agents, many research groups are 
now engaged in medicinal plants research. 
 
2. Materials and methods 
2.1 Plant Material 
The plant  Swertia chirata was selected based on 
variety of its medicinal value. The Swertia 
chirata was collected at their fully mature form, 
from local market (Khatunghang, Chittagong). It 
was then separated, cleaned from impurities. 
 
2.2 Extraction & Preparation of the plant 
sample 
The plant Swertia chirata was then subjected for 
shade dry at temperature not exceeding 50 ºC. 
Then they were ground into coarse powder with 
help of a grinder. The dry powder was then 
subjected to cold extraction with ethanol and then 
fractionation by Chloroform and Petroleum ether. 
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Fig 1: Percent clot lysis of Ethanol extract, Chloroform fraction of 
Swertia chirata and Standard Streptokinase. 
 
2.3 In vitro Thrombolysis Activity 
Phosphate buffered saline (PBS) (5 ml) was 
added to the commercially available lyophilized 
streptokinase vial (15, 00,000 I.U.) and mixed 
properly. This suspension was used as a stock 
from which appropriate dilutions were made to 
observe the thrombolytic activity. Experiments 
for clot lysis were carried as reported.[22] In brief; 
2 ml venous blood drawn from healthy volunteers 
was distributed in three different pre weighed 
sterile micro centrifuge tube (0.5 ml/tube) and 
incubated at 37 °C for 45 minutes. After clot 
formation, serum was completely removed 
(aspirated out without disturbing the clot formed) 
and each tube having clot was again weighed to 
determine the clot weight (clot weight = weight 
of clot containing tube – weight of tube alone). 
To each micro centrifuge tube containing pre-
weighed clot, 100 μl of ethanol extract (10 
mg/ml) of was added. As a positive control, 100 
μl of streptokinase and as a negative non-
thrombolytic control, 100 μl of distilled water 
were separately added to the control tubes 
numbered. All the tubes were then incubated at 
37 °C for 90 minutes and observed for clot lysis. 
After incubation, fluid released was removed and   
tubes were again weighed to observe the 
difference weight after clot disruption. Difference 
obtained in weight   taken before and after clot 
lysis was expressed as constant oxygen supply for 
48 hours.  
 
2.4 In-vitro Anti-inflammatory activity 
The ethanol extract of Swertia chirata was 
screened for anti‐inflammatory activity using 
inhibition of albumin denaturation technique 
which was studied according to Mizushima and 
Kobayashi with slight modification.[23, 24, 25] The 
standard drug and extract were dissolved in 
minimum quantity of dimethylformamide (DMF) 
and diluted with phosphate buffer (0.2 M, pH 
7.4). Final concentration of DMF in all solution 
was less than 2.5%. Test solution (1ml) 
containing different concentrations of drug was 
mixed with 1 ml of 1mM albumin solution in 
phosphate buffer and incubated at 27±1 °C in 
BOD incubator for 15 min. Denaturation was 
induced by keeping the reaction mixture at 60±1 
°C in water bath for 10 min. After cooling, the 
turbidity was measured at 660 nm. Percentage of 
inhibition of denaturation was calculated from 
control where no drug was added. Each 
experiment was done in triplicate and average is 
taken. The Acetyl Salicylic Acid was used as 
standard drug. The percentage inhibition of 
denaturation was calculated by using following 
formula.  
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% of Inhibition = 100 X { Vt / Vc – 1 } 
        
Where, 
Vt = Mean absorbance of test sample.                        
Vc = Mean absorbance of control 
 
 
3. Results 
3.1 Result of Thrombolytic Activity 
In thrombolytic activity using in vitro clot lysis 
assay method, the crude ethanol extract and 
chloroform fraction showed average clot lysis of 
46.096% and 31.87% while the standard 
streptokinase showed 69.35% which is shown in 
Figure-1. The percentage of clot lysis was found 
to be significant when compared with the vehicle 
control.  
 
3.2 Result of Anti-inflammatory activity 
Anti-inflammatory activity was measured by 
measuring the absorbance of treatment groups 
and converting it into total inhibition of protein 
denaturation. The statistical data were obtained 
significant below the P-value<0.5 (p<0.001). 
Percent inhibition of protein denaturation was 
calculated as follows:   
 
%Inhibition= (Abs control - Abs sample)/Abscontrol×100. 
 
In the present study for in-vitro anti-inflammatory 
test, the 1000 mg/kg of crude ethanol extract of 
Swertia chirata showed mean inhibition of 
protein denaturation 45.31±0.000576 and 
whereas for Acetyl Salicylic Acid, it was found to 
be 50.00±0.00177. 
 
Table 1: In- vitro of anti-inflammatory activity of Swertia chirata 
 
Observation Mean  Absorbance  ±SD  %MIPD  Total Inhibition of Protein Denaturation  
(%MIPD±SEM) 
ETHANOL 
(Vehicle Control)  0.064±0.00416  0 
 
0.00±0.00294 
 
ASA 
(Positive control)  0.032±0.00416  50 
 
50.00±0.00177 
 
EESC 
1000mg/kg  0.035±0.00416 45.31  45.31±0.000576 
ASA= Acetyl Salicylic acid, 
MIPD= Mean inhibition of Protein denaturation, 
EESC= Ethanol Extract of Swertia chirata. 
SEM= Standard error of mean, 
Total inhibition of protein denaturation= %MIPD±SEM,ap<0.001 
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Fig 2: % MIPD of Ethanol, ASA and EESC. 
 
4. Discussion and conclusion 
The result of this work showed that the extract of 
Swertia chirata had mild to moderate ani-
inflammatory activity (Table 1). The results of 
clot lysis was indicated that test samples showed 
different thrombolytic activity e at different 
concentration. The clot lysis of Swertia chirata 
was found to be increased with the increase with 
the concentration of the sample. The significant 
average percent of clot lysis (46.096%) of ethanol 
extract of Swertia chirata was found. Therefore, 
it is evident that the test sample and ethanol 
extract were thrombolytic and possess anti- 
inflammatory activity as well as biologically 
active. 
 
In conclusion, it can be claimed that Swertia 
chirata possesses significant anti-inflammatory 
activity as well as thrombolytic activity. In 
addition, positive result in thrombolytic activity 
test led us to the interference that the plant extract 
may contain bioactive compounds, which may 
aid ongoing cardiovascular drug discovery from 
the floristic resources. Hence, further studies are 
suggested to be undertaken to pin point the exact 
compounds and to better, understand its actions 
scientifically. 
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